Home Tags Lixte Biotechnology Holdings

Tag: Lixte Biotechnology Holdings

LIXTE Biotechnology Provides Update on Clinical Progress and Expanding Collaborations
Nasdaq

LIXTE Biotechnology Provides Update on Clinical Progress and Expanding Collaborations

GlobeNewswire -
0
LIXTE Biotechnology Holdings Announces the Passing of its Founder, John S. Kovach
Nasdaq

LIXTE Biotechnology Holdings Announces the Passing of its Founder, John S. Kovach

GlobeNewswire -
0
LIXTE Appoints Bas van der Baan as President and Chief Executive Officer
Nasdaq

LIXTE Appoints Bas van der Baan as President and Chief Executive Officer

GlobeNewswire -
0
LIXTE Biotechnology Announces a Supported Collaborative Trial to Study LIXTE’s First-in-Class PP2A Inhibitor, LB-100, Plus GSK’s Immunotherapy, Dostarlimab, in Clear-Cell Ovarian Cancer
Nasdaq

LIXTE Biotechnology Announces a Supported Collaborative Trial to Study LIXTE’s First-in-Class PP2A Inhibitor, LB-100, Plus GSK’s Immunotherapy, Dostarlimab, in Clear-Cell Ovarian Cancer

GlobeNewswire -
0
LIXTE Biotechnology Announces Closing of $3.5 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market under Nasdaq Rules
Nasdaq

LIXTE Biotechnology Announces Closing of $3.5 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market under Nasdaq Rules

GlobeNewswire -
0
LIXTE Biotechnology Announces Pricing of $3.5 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market under Nasdaq Rules
Nasdaq

LIXTE Biotechnology Announces Pricing of $3.5 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market under Nasdaq Rules

GlobeNewswire -
0
Preclinical Results of LIXTE Biotechnology’s Collaboration with Netherlands Cancer Institute Reveal Novel Mechanism by which LIXTE’s Lead Clinical Compound LB-100 Enhances Effectiveness of Immunotherapy and Chemotherapy
Nasdaq

Preclinical Results of LIXTE Biotechnology’s Collaboration with Netherlands Cancer Institute Reveal Novel Mechanism by which LIXTE’s Lead Clinical Compound LB-100 Enhances Effectiveness of Immunotherapy and Chemotherapy

GlobeNewswire -
0
LIXTE Biotechnology Holdings, Inc. Regains Compliance with Nasdaq Continued Listing Requirements
Nasdaq

LIXTE Biotechnology Holdings, Inc. Regains Compliance with Nasdaq Continued Listing Requirements

GlobeNewswire -
0
LIXTE Biotechnology and the Spanish Sarcoma Group Enroll First Patient in a Phase 1b/2 Randomized Trial of Doxorubicin +/- LIXTE’s Lead Anti-Cancer Compound, LB-100, in Advanced Soft Tissue Sarcomas
Nasdaq

LIXTE Biotechnology and the Spanish Sarcoma Group Enroll First Patient in a Phase 1b/2 Randomized Trial of Doxorubicin +/- LIXTE’s Lead Anti-Cancer Compound, LB-100, in Advanced Soft Tissue Sarcomas

GlobeNewswire -
0
LIXTE Biotechnology Holdings, Inc. Announces 1-for-10 Reverse Stock Split of its Common Stock Effective on Pre-Market Opening on June 5, 2023
Nasdaq

LIXTE Biotechnology Holdings, Inc. Announces 1-for-10 Reverse Stock Split of its Common Stock Effective on Pre-Market Opening on June 5, 2023

GlobeNewswire -
0
12Page 1 of 2

ABOUT US

Business Headline is a digital news publication that covers a wide range of topics from India and around the world. We focuses on bringing our readers the latest news related to business, with a particular emphasis on the Global Market . Business Headline keeps its readers updated with all the latest news related to Business, Markets, Technology, Entertainment and Sports.

Contact us: contact@businessheadline.in

FOLLOW US

Copyright © 2023 Business Headline. All Rights Reserved.

error: